Roche: to present new data at upcoming lung cancer congress
(CercleFinance.com) - Roche plans to present new data from its clinical development programme across different types of lung cancer at the International Association for the Study of Lung Cancer (IASLC) conference, which will be held in Toronto at the end of September.
The Swiss drugmaker said that 10 of its abstracts have been accepted, including three 'late breakers' and five oral presentations.
In particular Roche will unveil new and updated pivotal data from the Tecentriq lung program, including overall survival and progression-free survival results from a Phase III study in extensive-stage small cell lung cancer.
The company will also present new integrated pivotal results for entrectinib in non-small cell lung cancer, including a Phase II basket study.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The Swiss drugmaker said that 10 of its abstracts have been accepted, including three 'late breakers' and five oral presentations.
In particular Roche will unveil new and updated pivotal data from the Tecentriq lung program, including overall survival and progression-free survival results from a Phase III study in extensive-stage small cell lung cancer.
The company will also present new integrated pivotal results for entrectinib in non-small cell lung cancer, including a Phase II basket study.
Copyright (c) 2018 CercleFinance.com. All rights reserved.